Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm(TM) for the Treatment of Severe Allergic Reactions

Stock Information for Brightcove Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Brightcove Inc.

Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock
Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm(TM) (epinephrine) Sublingual Film
Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer
Aquestive Therapeutics Provides International Expansion Update for Anaphylm(TM) (epinephrine) Sublingual Film
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.